The dismal prognosis of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) prompted recent advances in the field of therapeutic approaches beyond cytotoxic cancer therapy. In recent years, the deeper and increasing knowledge on the genomic landscape and the upcoming new data on immunotherapy enacted by HNSCCs have led to successful therapeutic targeting of the immune system. Immune checkpoint inhibitors (ICIs) have changed state of the art in R/M patients and could have a potential role even in early disease. The purpose of this work is to summarize the role of immunotherapy for R/M HNSCC in clinical practice, with insights about future perspectives. Updated immunotherapy results in other R/M head and neck cancers such as thyroid, salivary glands, nasopharynx, sinonasal cancers, and nuclear protein in testis (NUT) are presented.

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies / S. Cavalieri, D.M. Filippini, A. Ottini, C. Bergamini, C. Resteghini, E. Colombo, R. Lombardo, I. Nuzzolese, S. Alfieri, L. Licitra, L.D. Locati. - 2:6(2021), pp. 522-542. [10.37349/etat.2021.00062]

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies

S. Cavalieri
Primo
;
A. Ottini;C. Bergamini;C. Resteghini;R. Lombardo;L. Licitra
Penultimo
;
2021

Abstract

The dismal prognosis of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) prompted recent advances in the field of therapeutic approaches beyond cytotoxic cancer therapy. In recent years, the deeper and increasing knowledge on the genomic landscape and the upcoming new data on immunotherapy enacted by HNSCCs have led to successful therapeutic targeting of the immune system. Immune checkpoint inhibitors (ICIs) have changed state of the art in R/M patients and could have a potential role even in early disease. The purpose of this work is to summarize the role of immunotherapy for R/M HNSCC in clinical practice, with insights about future perspectives. Updated immunotherapy results in other R/M head and neck cancers such as thyroid, salivary glands, nasopharynx, sinonasal cancers, and nuclear protein in testis (NUT) are presented.
Head and neck cancer; immune checkpoint inhibitors; rare cancer
Settore MED/06 - Oncologia Medica
2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
040.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.94 MB
Formato Adobe PDF
1.94 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/967303
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
social impact